Navigation Links
Vion Pharmaceuticals Holds Special Meeting of Stockholders

Stockholders Approve Board Authority to Implement Reverse Stock Split and

Reduce the Number of Total Shares and Authorized Shares

NEW HAVEN, Conn., Feb. 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced that a Special Meeting of Stockholders was held at the Omni Hotel in New Haven, Connecticut today at 10:00 Eastern Time.

At the meeting, shareholders voted to approve amendments to the Company's Restated Certificate of Incorporation to:

-- effect a reverse stock split of the Company's outstanding common stock

of not less than 1-for-5 and not more than 1-for-10, with the exact

ratio to be set within that range by the Board of Directors without

further approval by stockholders; and

-- decrease the total number of shares and the number of shares of common

stock that the Company is authorized to issue.

Alan Kessman, Chief Executive Officer, said, "We are pleased that our shareholders have authorized our Board of Directors to implement a reverse stock split. We will now determine the appropriate split ratio to establish a price for our common stock allowing us to regain compliance with Nasdaq's listing requirements."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, w

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
(Date:7/24/2014)... , July 24, 2014   Cypher ... today the appointment of Adam Simpson ... Genomics provides rapid and comprehensive annotation and interpretation ... clinical reporting. "Cypher,s technology has the ... healthcare by enhancing diagnostic accuracy, optimizing therapeutic approaches ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... in the sensitivity of weighing scales. Using the same ... functional nanotube radio, researchers with Berkeley Lab and the ... nanoelectromechanical system (NEMS) that can function as a scale ... atom of gold. , Alex Zettl, a physicist who ...
... SAN DIEGO, July 28 Ardea Biosciences, Inc.,(Nasdaq: ... be presented on RDEA806, the,Company,s novel investigational non-nucleoside ... virus (HIV) at,the 48th Annual ICAAC/IDSA 46th Annual ... Dr. Graeme Moyle, Director of HIV Research, Chelsea ...
... at IMAPS 2008 , ... Washington, D.C. (PRWEB) July ... proud to announce that Governor Carcieri and Dr Zolper have agreed ... on Microelectronics (IMAPS ,08) at the Providence, RI, Convention Center, November ...
Cached Biology Technology:Golden scales 2Golden scales 3Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 3Rhode Island Governor Donald L. Carcieri and Dr. John C. Zolper, Vice President, Raytheon Company to Speak at IMAPS 2008 2
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... research out of York University shows a surprisingly effective ... grass fungus: moose saliva (yes moose saliva). , ... saliva inhibits a grassendophyte mutualism" shows that moose and ... hosts a fungus called epichlo festucae that produces the ... toxicity. , "Plants have evolved defense mechanisms to protect ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Moose drool inhibits growth of toxic fungus: York U research 2New imaging agent provides better picture of the gut 2
... children and young adults for influenza is being seriously underestimated, ... historic vaccine programs have concentrated on the elderly and those ... computer modeling analysis was just published in the journal ... Health. The study suggests that children in school and young ...
... June 11, 2013 (BRONX, NY) Today, researchers ... Yeshiva University convened a one-day conference on Jewish genetics ... research. Such research could help scientists identify causes and ... common disorders afflicting the general population. The ...
... guarantee future support for international scientific collaborations funded by ... on a three year budgetary framework will extend the ... At an Intergovernmental Conference hosted by the European Commission ... governments that support the Human Frontier Science Program came ...
Cached Biology News:Flu vaccines aimed at younger populations could break annual transmission cycle 2Flu vaccines aimed at younger populations could break annual transmission cycle 3Albert Einstein College of Medicine hosts conference on Jewish genetic research 2
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: